53Ga0.47As base, and a 75-nm-thick In0.53Ga0.47As collector. The emitter enables fabrication of a 15-nm-thick ledge structure simply by wet etching the n(+)-InGaAs

emitter. The emitter mesa and base metal were scaled down to 0.25 and 0.3 mu m, respectively. The fabricated HBT with a 0.25-mu m emitter provides a current gain of 62 at a collector current density, J(c), of 10 mA/mu m(2). With the thin ledge structure, the current gain is virtually independent of emitter size and emitter-base spacing. The HBT also exhibits an f(t) of 442 GHz and an f(max) of 214 GHz at a J(c) of 12 mA/mu m(2). The results of bias-temperature stress tests show that base and collector currents are stable up to 1042 h at a J(c) of 5 mA/mu m(2). (C) 2010 The Japan Society of Applied Physics”
“We Stem Cell Compound Library manufacturer have succeeded in synthesizing organic biradical crystals of m-Ph-V-2 [= 1,3-bis-(1,5-diphenylverdazyl-3-yl)benzene]. The intra and intermolecular interactions, which are deduced

from the molecular packing in the crystal, are considered to form an alternating double chain. We evaluated the intramolecular ferromagnetic ( FM) interaction from an analysis of the magnetic susceptibility of isolated m-Ph-V-2 molecules. We analyzed the magnetic susceptibility and magnetization curves of the crystals by the quantum Monte Carlo method and successfully explained these CX-6258 solubility dmso properties using an S = 1/2 FM alternating double chain model, which consists of antiferromagnetically coupled FM alternating chains. In addition, the magnetic susceptibility and specific heat showed anomalous behavior at T-N = 1.9 K, which indicates the magnetic phase transition to an antiferromagnetically ordered state.”
“Increasing life expectancy and PSA testing has increased the number of men over the age of seventy-five presenting for investigation of potential prostate malignancies. Prostatic biopsies provide diagnostic information; however, they are invasive and may not alter

management decisions. Therefore, this study aimed to investigate whether prostate biopsies in this age group were justified. All men aged 75 years and older who underwent prostatic biopsies between January 2010 and November 2011 at Bedford Hospital were identified Cell Cycle inhibitor and the indication for the biopsies, histopathological results and subsequent management plan investigated. One hundred and thirty-eight (138) prostatic biopsies were undertaken and malignancies identified in 60/138 (43 %) cases. Prebiopsy PSA and examination findings had a poor positive predictive value of 54 %. Fifty-five out of sixty (92 %) cancers were classified as high or medium risk disease with 30/60 (50 %) patients commencing radiotherapy treatment with curative intent. In selected patients aged 75 years or over, prostatic biopsies provide important diagnostic information which directly impacts on clinical decisions, supporting their use in this age group.